Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1)
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Century Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06255028
- Locations
- 🇺🇸
Keck School of Medicine of University of Southern California, Los Angeles, California, United States
🇺🇸Lurie Children's; Northwestern Medicine - Northwestern Medical Group, Chicago, Illinois, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT06237881
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06138587
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 128
- Registration Number
- NCT06119685
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States
TIL Therapy for Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- NeogenTC
- Target Recruit Count
- 12
- Registration Number
- NCT06107894
Phase II Clinical Trial of Interleukin-2 in AD
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06096090
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT05903937
HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- BGI, China
- Target Recruit Count
- 12
- Registration Number
- NCT05895370
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 154
- Registration Number
- NCT05883449
- Locations
- 🇺🇸
UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- TCRCure Biopharma Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05881525
- Locations
- 🇨🇳
TCRCure Biopharma Ltd., Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.